Rapport Therapeutics, Inc. 4

CEO Abraham Ceesay sold 8,210 shares of Rapport Therapeutics, Inc. common stock on 2026-09-08 for approximately $373,000 under a Rule 10b5-1 plan.

On 2026-09-08, Abraham Ceesay, Chief Executive Officer of Rapport Therapeutics, Inc., sold a total of 8,210 shares of the company’s common stock in two open-market transactions under a Rule 10b5-1 trading plan adopted on March 27, 2026. The sales consisted of 7,141 shares at a weighted average price of approximately $45.555 per share and 1,069 shares at a weighted average price of approximately $46.0147 per share, for aggregate proceeds of roughly $373,000. Following these transactions, Ceesay retained direct ownership of 458,977 shares, and there were additional indirect holdings of 81,729 shares by the Ceesay Family Irrevocable Trust and 20,729 shares by the Dorothy Ceesay Irrevocable Trust, indicating that he continues to hold a significant equity stake in the company despite the programmed sales.

Filing Facts

CIK

2012593

Ticker

RAPP

Form

4

Source Type

fda

Accession

0001193125-26-386436

Alert Tier

6